Taken together, these data nominate fluorinated coumarins, particularly compound 19, as a promising multitarget chemotype combining VEGFR-2 and p38α MAPK modulation with demonstrable antiproliferative effects, warranting in vivo evaluation and pharmacokinetic optimization for breast and cervical cancer applications [63]. The gene discussed is KDR; the disease is cervical carcinoma.